Hyaluronic acid-modified cationic nanoparticles overcome enzyme CYP1B1-mediated breast cancer multidrug resistance

被引：18
作者：
Zhang, Jun [1 ]
Song, Jia [1 ]
Liang, Xiao [1 ]
Yin, Yunzhi [1 ]
Zuo, Tiantian [1 ]
Chen, Daijie [1 ]
Shen, Qi [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Pharm, 800 Dongchuan Rd, Shanghai 200240, Peoples R China
来源：
NANOMEDICINE | 2019年 / 14卷 / 04期
关键词：
alpha-napthtoflavone; breast cancer; CD44; CYP1B1; DTX; hyaluronic acid; lysosome escape; multidrug resistance; nanoparticles; polyethyleneimine; MESOPOROUS SILICA; ANTICANCER DRUGS; DELIVERY; DOCETAXEL; MICELLES; CYP1B1; CYTOCHROME-P450; PACLITAXEL; CELLS; FORMULATIONS;
D O I：
10.2217/nnm-2018-0244
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Aim: Enzyme CYP1B1 (CYP1B1) is usually overexpressed in multidrug resistance (MDR) breast cancer cells, which could metabolically inactivate docetaxel (DTX). Materials & methods: The cationic core-shell nanoparticles (hyaluronic acid/polyethyleneimine nanoparticles[HA/PEI NPs]) modified with hyaluronic acid (HA) were developed and coloaded with DTX and alpha-napthtoflavone (ANF, a CYP1B1 inhibitor) to overcome MDR in breast cancer induced by CYP1B1. Physicochemical characterization, MDR reversing effect in vitro and pharmacokinetics in vivo of HA/PEI NPs were evaluated. Results: The HA/PEI NPs exhibited spherical morphology with size of (193.6 +/- 3.1) nm. The HA/PEI NPs could reverse MDR effectively by downregulating the expression of CYP1B1. The HA/PEI NPs improved the bioavailability of DTX. Conclusion:The HA/PEI NPs might be a promising strategy to overcome CYP1B1-mediated breast cancer MDR. [GRAPHICS]
引用
收藏
页码：447 / 464
页数：18
相关论文
共 50 条
  • [31] Long-term cadmium exposure induces epithelial-mesenchymal transition in breast cancer cells by activating CYP1B1-mediated glutamine metabolic reprogramming in BT474 cells and MMTV-Erbb2 mice
    Li, Jingdian
    Gao, Peng
    Qin, Mingke
    Wang, Junhua
    Luo, Yan
    Deng, Ping
    Hao, Rongrong
    Zhang, Lei
    He, Mindi
    Chen, Chunhai
    Lu, Yonghui
    Ma, Qinlong
    Li, Min
    Tan, Miduo
    Wang, Liting
    Yue, Yang
    Wang, Hui
    Tian, Li
    Xie, Jia
    Chen, Mengyan
    Yu, Zhengping
    Zhou, Zhou
    Pi, Huifeng
    SCIENCE OF THE TOTAL ENVIRONMENT, 2024, 918
  • [32] Enniatin B1 is a substrate of intestinal P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein
    Ivanova, L.
    Uhlig, S.
    Eriksen, G. S.
    Johannessen, L. E.
    WORLD MYCOTOXIN JOURNAL, 2010, 3 (03) : 271 - 281
  • [33] Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1
    Qi, Xiaozhe
    Wagenaar, Els
    Xu, Wentao
    Huang, Kunlun
    Schinkel, Alfred H.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017, 329 : 18 - 25
  • [34] Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells
    Liu, Dao-Lu
    Li, Ying-Jie
    Yang, Dong-Hua
    Wang, Chen-Ran
    Xu, Jun
    Yao, Nan
    Zhang, Xiao-Qi
    Chen, Zhe-Sheng
    Ye, Wen-Cai
    Zhang, Dong-Mei
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 46 (05) : 2029 - 2038
  • [35] A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1-and ABCG2-Mediated Multidrug Resistance in Cancer Cells
    Guo, Chao
    Liu, Fangyuan
    Qi, Jie
    Ma, Jiahui
    Lin, Shiqi
    Zhang, Caiyun
    Zhang, Qian
    Zhang, Hangyu
    Lu, Rong
    Li, Xia
    MOLECULES, 2018, 23 (12):
  • [36] Folic Acid-Modified miR-491-5p-Loaded ZIF-8 Nanoparticles Inhibit Castration-Resistant Prostate Cancer by Regulating the Expression of EPHX1
    Ju, Guanqun
    Liu, Bing
    Ji, Mingfei
    Jin, Rui
    Xu, Xiaojian
    Xiao, Yongshuang
    Li, Jie
    Xu, Dongliang
    Huang, Yuhua
    Hou, Jianquan
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2021, 9
  • [37] Metabolic Intervention Nanoparticles for Triple-Negative Breast Cancer Therapy via Overcoming FSP1-Mediated Ferroptosis Resistance
    Yang, Jie
    Jia, Zengguang
    Zhang, Jun
    Pan, Xiuhua
    Wei, Yawen
    Ma, Siyu
    Yang, Ning
    Liu, Zengyi
    Shen, Qi
    ADVANCED HEALTHCARE MATERIALS, 2022, 11 (13)
  • [38] Hyaluronic acid-chitosan nanoparticles for co-delivery of M1R-34a and doxorubicin in therapy against triple negative breast cancer
    Deng, Xiongwei
    Cao, Minjun
    Zhang, Jiakun
    Hu, Kelei
    Yin, Zhaoxia
    Zhou, Zhixiang
    Xiao, Xiangqian
    Yang, Yishu
    Sheng, Wang
    Wu, Yan
    Zeng, Yi
    BIOMATERIALS, 2014, 35 (14) : 4333 - 4344
  • [39] Synergistic triple-combination therapy with hyaluronic acid-shelled PPy/CPT nanoparticles results in tumor regression and prevents tumor recurrence and metastasis in 4T1 breast cancer
    Sun, Wei
    Du, Yang
    Liang, Xiaolong
    Yu, Chunyao
    Fang, Junjie
    Lu, Wei
    Guo, Xiuyu
    Tian, Jie
    Jin, Yinhua
    Zheng, Jianjun
    BIOMATERIALS, 2019, 217
  • [40] Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806
    Rincon, Mercedes
    Broadwater, Gloria
    Harris, Lyndsay
    Crocker, Abigail
    Weaver, Donald
    Dressler, Lynn
    Berry, Donald
    Sutton, Linda
    Michaelson, Richard
    Messino, Michael
    Kirshner, Jeffrey
    Fleming, Gini
    Winer, Eric
    Hudis, Clifford
    Appel, Stacy
    Norton, Larry
    Muss, Hyman
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (03) : 301 - 308
12345